Nanoscope Therapeutics appointed Damon Daulerio as Executive Director of Regulatory Affairs to strengthen its regulatory leadership as it advances MOGENRY, an investigational gene therapy for inherited retinal diseases. Daulerio brings 30 years of pharmaceutical industry experience, including leadership roles in regulatory affairs at Insmed, Novartis, and Alcon, with expertise in ophthalmology, rare diseases, and global drug approvals. He will oversee Nanoscope's global regulatory strategy and coordinate with regulatory agencies in the United States, Europe, and Japan as MOGENRY progresses through review and toward potential commercialization.
